Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market

APAC Bladder Cancer Therapeutics & Diagnostics Market Analysis

The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market is expected to register a CAGR of 5% during the forecast period.

APAC Bladder Cancer Therapeutics & Diagnostics Market Trends

Bladder Ultrasound is Expected to Show a Steady Growth During the Forecast Period

Bladder Ultrasound is one of the type of diagnostic device which uses sound waves to detect and analyze the cancer present in the bladder. The growing incidence of bladder cancer and new devices are being developed for the diagnosis of cancer are expected to stimulate the growth in this segment. According to the Globocan, 2018, almost 4,249 incidences of bladder cancer were observed in the Korea Republic of with around 1,712 deaths. Ultrasound is the most common method used in diagnosing the early stages of cancer due to its specificity. Hence, it is expected to boost the demand for ultrasound devices in the market during the forecast period.

APAC Bladder Cancer Therapeutics & Diagnostics Industry Overview

Some of the key players in the market are AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Endo Pharmaceuticals Inc. and Johnson & Johnson. Companies are constantly indulged in developing the products related to diagnosis and treatment of the bladder cancer to grow their presence in the market. In 2018, Merck recieved an approval from Japanese Ministry of Health, Labor and Welfare (MHLW) for it's product Keytruda (MSD) which is used for the treatment of urothelial cancer patients.

APAC Bladder Cancer Therapeutics & Diagnostics Market Leaders